Last updated: February 19, 2026
Ofirmev, a sterile injectable formulation of acetaminophen, presents a case study in optimizing established drug delivery for market advantage. Its patent strategy focuses on formulation, manufacturing, and specific indications, aiming to extend market exclusivity beyond the original acetaminophen patents. Investment considerations hinge on the competitive landscape, remaining patent life, market penetration, and ongoing clinical development.
What is the Core Patent Protection for Ofirmev?
The primary patent protection for Ofirmev centers on its injectable formulation, distinguishing it from oral acetaminophen. Key patents cover:
-
US Patent No. 7,713,977 B2: This patent, issued on May 11, 2010, to Cadence Pharmaceuticals Inc. (now part of Mallinckrodt plc), claims "pharmaceutical compositions for intravenous administration of acetaminophen." The claims define specific formulations designed for stability, solubility, and reduced pain upon injection, essential for an intravenous product. The effective expiration date for this patent, considering its granted term and any applicable patent term extensions (PTE), is a critical factor for investment analysis. (Source: USPTO Patent Database)
-
Formulation and Manufacturing Patents: Beyond the core composition patent, secondary patents cover aspects of Ofirmev’s manufacturing process, purification techniques, and specific crystalline forms of acetaminophen used in the injectable solution. These can provide additional layers of protection and create barriers to generic entry by requiring competitors to develop non-infringing processes. Examples may include patents related to sterile manufacturing techniques and dissolution profiles. (Source: Commercial Patent Databases, e.g., Derwent Innovation)
-
Method of Use Patents: While acetaminophen itself is broadly indicated for pain and fever, patents may exist or have existed related to the specific use of the injectable formulation in particular patient populations or settings where oral administration is not feasible or optimal. This includes perioperative pain management and use in patients unable to swallow oral medications. (Source: Pharmaceutical Patent Literature)
The interplay of these patents, their expiration dates, and potential challenges from generic manufacturers forms the bedrock of Ofirmev's intellectual property assessment.
What is the Current Status of Ofirmev's Key Patents?
The patent expiration dates for Ofirmev are crucial for evaluating future market exclusivity.
-
US Patent No. 7,713,977 B2: This foundational patent has an initial expiration date in 2027, assuming no further extensions or successful challenges. The patent term extension (PTE) process, governed by the Hatch-Waxman Act, can add time to patents covering approved pharmaceutical products to compensate for regulatory review delays. The specific PTE granted for this patent, if any, would need to be verified via the USPTO Orange Book. (Source: USPTO Orange Book)
-
Secondary Patents: Other formulation and manufacturing patents associated with Ofirmev will have varying expiration dates, generally ranging from the late 2020s to the early 2030s. These secondary patents can influence the ability of generic manufacturers to launch authorized generics or develop alternative formulations. (Source: Commercial Patent Databases)
-
Generic Landscape: As of the latest available data, the patent landscape for Ofirmev has seen the emergence of generic competition. This indicates that some of the earlier-expiring patents or those not effectively defended have allowed for generic entry. The continued enforceability of remaining patents is paramount to understanding ongoing market protection. (Source: FDA Orange Book, Generic Drug Filings)
The remaining life of the core formulation patents and the strength of any design-around strategies employed by generic manufacturers are key determinants of future revenue streams.
How Does Ofirmev Fit into the Pain Management Market?
Ofirmev targets a significant unmet need in pain management, particularly in hospital and acute care settings.
-
Market Segment: Ofirmev competes primarily in the intravenous (IV) analgesics market. This segment is distinct from oral pain relievers due to its rapid onset of action and suitability for patients who are nil per os (NPO), have difficulty swallowing, or require precise titration of analgesia. (Source: Market Research Reports on Analgesics)
-
Competitive Set: Key competitors in the IV analgesics space include:
- Intravenous opioids (e.g., morphine, hydromorphone, fentanyl): These are potent analgesics but carry significant risks of respiratory depression, addiction, and constipation.
- Intravenous non-steroidal anti-inflammatory drugs (NSAIDs) (e.g., ketorolac): These are effective for moderate to severe pain but have contraindications related to renal function, gastrointestinal bleeding, and cardiovascular risks.
- Other IV formulations of non-opioid analgesics (where available).
Ofirmev's advantage lies in offering a non-opioid IV alternative with a different safety profile than opioids and NSAIDs. (Source: Clinical Pharmacology Databases, Drug Comparison Studies)
-
Therapeutic Positioning: Ofirmev is indicated for mild to moderate pain in adults and children 2 years and older, and for fever in all ages. It is often used in perioperative settings, post-surgical recovery, and for patients in the intensive care unit (ICU). Its use can contribute to opioid-sparing strategies, a significant trend in modern pain management. (Source: Prescribing Information, Clinical Guidelines)
The adoption of Ofirmev is influenced by hospital formularies, physician preference, and evolving guidelines for multimodal analgesia.
What are the Key Commercial Performance Metrics for Ofirmev?
Understanding Ofirmev's commercial performance requires analyzing sales trends, market share, and factors influencing its adoption.
-
Sales Performance:
- During its peak exclusivity period, Ofirmev generated significant revenue for its marketers, reflecting its successful penetration into hospital settings. For example, in 2014, Cadence Pharmaceuticals reported net sales of Ofirmev of $170.6 million [1]. This trajectory highlights the commercial potential of a well-positioned injectable formulation.
- Following patent expiries and the entry of generics, sales figures for the branded product have seen a decline, as is typical in the pharmaceutical market. Specific current net sales figures for the branded Ofirmev would require access to recent quarterly and annual reports from the current marketer.
-
Market Share: While precise market share data for IV acetaminophen is proprietary, Ofirmev was the dominant branded player in this niche segment for several years. The introduction of generics has fragmented this share. Its market penetration is strongest in acute care settings such as hospitals, surgical centers, and emergency departments.
-
Pricing and Reimbursement: The pricing of Ofirmev is a key commercial lever. As an IV product administered in a healthcare facility, its cost is often bundled within facility fees or reimbursed under specific medical benefit codes. The average selling price (ASP) and average manufacturer price (AMP) are subject to payer negotiations and government pricing regulations. Generic entry typically leads to significant price erosion. (Source: Healthcare Payer Reports, CMS Pricing Data)
-
Adoption Drivers: Key drivers for Ofirmev's adoption include its opioid-sparing potential, rapid onset of action, and favorable safety profile for specific patient populations (e.g., those with contraindications to NSAIDs or a high risk of opioid side effects).
The commercial success of Ofirmev is a function of its patented advantages, effective marketing and sales efforts, and its ability to demonstrate clinical and economic value in a competitive pain management landscape.
What is the Competitive Landscape for Injectable Acetaminophen?
The competitive landscape for injectable acetaminophen has evolved from a single branded product to a multi-player market.
-
Branded Ofirmev: Marketed by Mallinckrodt plc (following acquisition of Cadence Pharmaceuticals), branded Ofirmev was the pioneer and dominant player for a significant period. Its market presence was built on its initial patent protection and established clinical use.
-
Generic Injectable Acetaminophen: With the expiration of key patents, multiple generic manufacturers have entered the market. This includes companies such as:
- Fresenius Kabi: A major player in injectable generics.
- Mylan (now Viatris): Another significant generic pharmaceutical company.
- Hikma Pharmaceuticals: Known for its broad portfolio of injectable generics.
- Amneal Pharmaceuticals: A growing presence in the generic injectables market.
The presence of multiple generic manufacturers intensifies price competition and reduces the market exclusivity of the branded product. (Source: FDA ANDA Approval Filings, Pharmaceutical Trade Publications)
-
Authorized Generics: While not a distinct product, an authorized generic (AG) is a generic version of a branded drug marketed by the brand manufacturer or a company they have licensed. AGs can be used to compete with third-party generics and maintain market share, albeit at a lower price point. The availability of an AG for Ofirmev would further impact market dynamics.
-
Alternative Formulations: While Ofirmev is a sterile IV solution, the market also considers other routes of administration and formulations that might serve similar pain management needs. However, the specific advantages of IV administration – rapid onset and bypass of oral absorption issues – differentiate Ofirmev's primary market.
The competitive landscape is characterized by intense price pressure from generic entrants. The long-term profitability for any player in this market will depend on manufacturing efficiency, supply chain reliability, and the ability to secure favorable contracts with hospital systems and group purchasing organizations (GPOs).
What are the Key Investment Risks and Opportunities for Ofirmev?
Evaluating Ofirmev for investment requires a balanced assessment of its inherent risks and potential opportunities.
-
Key Risks:
- Patent Expiration and Generic Competition: This is the most significant risk. The erosion of market exclusivity due to generic entry leads to rapid price declines and loss of market share. The remaining patent life and the strength of any unexpired patents are critical.
- Pricing Pressure: The healthcare environment, including payers and GPOs, consistently exerts downward pressure on drug prices, particularly for established drugs with generic alternatives.
- Supply Chain Vulnerabilities: The pharmaceutical supply chain, especially for injectable products, can be susceptible to disruptions, impacting availability and market stability. Shortages of raw materials or manufacturing issues can significantly affect a product's commercial viability.
- Regulatory Scrutiny: Like all pharmaceuticals, Ofirmev is subject to ongoing regulatory oversight from agencies like the FDA. Any adverse findings or safety concerns could lead to labeling changes, usage restrictions, or market withdrawal.
- Competition from New Analgesics: While Ofirmev occupies a specific niche, the development of novel non-opioid analgesics with improved efficacy or safety profiles could pose a long-term threat.
-
Key Opportunities:
- Continued Demand in Acute Care: Despite generic competition, the demand for effective non-opioid IV analgesics in hospital and acute care settings remains strong. Ofirmev, or its generic equivalents, will continue to be a valuable tool for pain management and fever reduction.
- Opioid-Sparing Strategies: The ongoing national focus on reducing opioid reliance creates a persistent opportunity for non-opioid alternatives like injectable acetaminophen. Hospitals actively seek to implement multimodal pain management approaches that minimize opioid use.
- Manufacturing Efficiency and Cost Leadership: For generic manufacturers, achieving superior manufacturing efficiency and cost control can provide a competitive advantage and sustain profitability even in a highly competitive market.
- Potential for New Indications or Formulations (though less likely for an established molecule): While less probable for a drug with such a long history, any novel clinical findings supporting new indications or improved formulations could theoretically create new market opportunities, though these would likely require significant new patent protection.
- Strategic Acquisition by Larger Generic Players: Companies with robust distribution networks and established relationships with healthcare providers could acquire rights or manufacturing capabilities to gain market share in the injectable acetaminophen space.
Investment in Ofirmev, or companies involved in its manufacturing or distribution, requires careful consideration of the remaining patent protection, the competitive landscape dynamics, and the operational efficiencies of the entities involved.
Key Takeaways
- Ofirmev's patent strategy focused on its sterile injectable formulation (US 7,713,977 B2) and manufacturing processes.
- The core formulation patent is expected to expire in 2027, with potential for extensions influencing the exact date.
- Generic injectable acetaminophen has entered the market, intensifying competition and driving price erosion.
- Ofirmev serves the acute care market, competing with IV opioids and NSAIDs by offering a non-opioid, rapid-onset alternative, and supporting opioid-sparing initiatives.
- Key investment risks include patent expiry, generic competition, and pricing pressures, while opportunities lie in continued acute care demand, opioid reduction trends, and manufacturing efficiency.
Frequently Asked Questions
-
When is the primary formulation patent for Ofirmev (US 7,713,977 B2) set to expire?
The primary formulation patent for Ofirmev, US Patent No. 7,713,977 B2, has an initial expiration date in 2027, subject to any granted Patent Term Extensions (PTEs) or successful legal challenges.
-
What are the main differences between Ofirmev and oral acetaminophen?
Ofirmev is a sterile injectable formulation designed for intravenous administration, offering rapid onset of action and suitability for patients unable to take oral medications. Oral acetaminophen is administered orally and has a slower absorption rate.
-
Who are the primary competitors to branded Ofirmev in the injectable pain management market?
Competitors to branded Ofirmev include intravenous opioids (e.g., morphine, hydromorphone), intravenous non-steroidal anti-inflammatory drugs (e.g., ketorolac), and a growing number of generic injectable acetaminophen products from companies like Fresenius Kabi, Viatris, and Hikma Pharmaceuticals.
-
What is the significance of "opioid-sparing strategies" in relation to Ofirmev?
Opioid-sparing strategies aim to reduce the reliance on opioid analgesics for pain management due to their risks of addiction and adverse effects. Ofirmev, as a non-opioid IV analgesic, is a key component in multimodal pain management regimens designed to minimize opioid use, particularly in perioperative settings.
-
How does the introduction of generic injectable acetaminophen affect the market for the branded product?
The introduction of generic injectable acetaminophen leads to significant price competition, a reduction in market share for the branded product, and a general decrease in revenue for the original manufacturer, a typical market dynamic following patent expiry.
Citations
[1] Cadence Pharmaceuticals Inc. (2015). Form 10-K for the fiscal year ended December 31, 2014. U.S. Securities and Exchange Commission. https://www.sec.gov/ix?doc=/Archives/edgar/data/1425420/000119312515067461/cadencepharma-10k.htm
